TScan Therapeutics remains a high-risk, pre-commercial biotechnology entity whose valuation is tethered to the successful execution of its broad hematologic and solid tumor pipeline. While the company maintains a current ratio of 6.65, its reliance on episodic...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.23+9.2% vs -$0.25 | $1M-43.9% vs $2M |
Q2 2026 May 6, 2026 | -$0.22+0.0% vs -$0.22 | $982,000-60.7% vs $3M |
Q2 2026 Mar 4, 2026 | -$0.18+33.3% vs -$0.27 | $3M+5.4% vs $2M |
Q4 2025 Nov 12, 2025 | -$0.28+20.0% vs -$0.35 | $3M+29.4% vs $2M |
BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Earnings and Valuation This table compares BioNTech and TScan
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners Workforce reduction of approximately 75% and strategic reorganization focuses resources on solid tumors and extends runway into Q4 2027 Company to host webcast today, September 2, at 8:30 a.m. ET WALTHAM, Mass.
Benchmark TCRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TScan Therapeutics, Inc. (TCRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.36 | $47.3M | -0.36 | 266.65% | -1256.81% | -71.28% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $1.15 | $2.81M | -0.52 | -50% | -133666.67% | -232.6% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $2.22 | $361.98M | -1.35 | — | — | -128.27% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — |
TScan Therapeutics, Inc. (TCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TScan Therapeutics, Inc. (TCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 18, 2026·SEC
Aug 12, 2026·SEC
Jun 22, 2026·SEC
Get notified when TCRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TScan Therapeutics, Inc. (TCRX) stock FAQ — growth, dividends, profitability & financials explained
TScan Therapeutics, Inc. (TCRX) reported $7.1M in revenue for fiscal year 2025.
TScan Therapeutics, Inc. (TCRX) grew revenue by 266.7% over the past year. This is strong growth.
TScan Therapeutics, Inc. (TCRX) reported a net loss of $117.7M for fiscal year 2025.
TScan Therapeutics, Inc. (TCRX) has a return on equity (ROE) of -71.3%. Negative ROE indicates the company is unprofitable.
TScan Therapeutics, Inc. (TCRX) had negative free cash flow of $118.4M in fiscal year 2025, likely due to heavy capital investments.
